ArticleFrontiers in immunology2026
Vitamin D boosts HIV-1 resistance in female genital epithelial cells by enhancing antiviral cathelicidin expression.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Elevated levels of serum Vitamin D (VitD) and increased expression of its receptor on peripheral blood cells have been reported in individuals who have been exposed to HIV-1 yet remain seronegative (HESN). This study aimed to investigate the potential antiviral role of VitD in the female genital epithelium, which constitutes the first physical barrier against HIV-1. We hypothesized that VitD may modulate susceptibility to HIV-1 infection by influencing epithelial functions such as tight junction integrity, production of antiviral peptides, and secretion of pro-inflammatory mediators. Methods: Endocervical (End1), ectocervical (Ect1) and vaginal (Vk2) epithelial cell lines were cultured in transwells and treated for 24 hours with VitD (1x10 Results: Pre-treatment of End1, Ect1 and Vk2 epithelial monolayers with VitD reduced HIV-infection of the CD4+ T cells in the basal chamber by 50%, 53%, and 31%, respectively. Only a fraction of the HIV-1 virion applied apically transmigrated across the epithelium. The infectivity of the residual apical HIV-1 virion in the VitD-pre-treated End1, Ect1, and VK2 cultures was reduced by 42%, 36%, and 25%, respectively. These reductions were accompanied by increased RNA transcripts encoding Cathelicidin Antimicrobial Peptide (CAMP) and elevated secretion of CAMP protein into the apical chamber. Conclusion: These findings provide evidence that VitD enhances the antiviral properties of female genital epithelium and reduces HIV-1 infectivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.